Sanofi India Limited (SANOFI.NS)
INR 6221.5
(0.23%)
INR 6221.5
(0.23%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 17.14 Billion INR | -17.23% |
| 2022 | 20.71 Billion INR | -32.32% |
| 2021 | 30.61 Billion INR | 4.88% |
| 2020 | 29.18 Billion INR | -10.05% |
| 2019 | 32.44 Billion INR | 8.73% |
| 2018 | 29.83 Billion INR | 7.45% |
| 2017 | 27.77 Billion INR | 9.33% |
| 2016 | 25.4 Billion INR | 5.63% |
| 2015 | 24.04 Billion INR | 7.95% |
| 2014 | 22.27 Billion INR | 20.75% |
| 2013 | 18.44 Billion INR | 13.09% |
| 2012 | 16.31 Billion INR | 8.57% |
| 2011 | 15.02 Billion INR | 6.68% |
| 2010 | 14.08 Billion INR | 16.85% |
| 2009 | 12.05 Billion INR | 13.14% |
| 2008 | 10.65 Billion INR | 16.36% |
| 2007 | 9.15 Billion INR | 6.68% |
| 2006 | 8.58 Billion INR | 23.53% |
| 2005 | 6.94 Billion INR | 21.59% |
| 2004 | 5.71 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2024 Q2 | 13.6 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 14.97 Billion INR | 0.0% |
| 2023 FY | 17.14 Billion INR | -17.23% |
| 2023 Q4 | 17.14 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 20.71 Billion INR | 0.0% |
| 2022 FY | 20.71 Billion INR | -32.32% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 21.76 Billion INR | 0.0% |
| 2021 Q4 | 30.61 Billion INR | 0.0% |
| 2021 Q2 | 24.89 Billion INR | 0.0% |
| 2021 FY | 30.61 Billion INR | 4.88% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 29.18 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 34.84 Billion INR | 0.0% |
| 2020 FY | 29.18 Billion INR | -10.05% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q2 | 29.9 Billion INR | 0.0% |
| 2019 FY | 32.44 Billion INR | 8.73% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 32.44 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 29.83 Billion INR | 7.45% |
| 2018 Q2 | 28.3 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 29.83 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2017 Q4 | 27.77 Billion INR | 0.0% |
| 2017 FY | 27.77 Billion INR | 9.33% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 26 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 25.4 Billion INR | 0.0% |
| 2016 FY | 25.4 Billion INR | 5.63% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 24.31 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 24.04 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 22.23 Billion INR | 0.0% |
| 2015 FY | 24.04 Billion INR | 7.95% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 18.69 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 22.27 Billion INR | 20.75% |
| 2014 Q4 | 22.27 Billion INR | 0.0% |
| 2013 Q2 | 16.52 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 18.44 Billion INR | 13.09% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q4 | 18.44 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 FY | 16.31 Billion INR | 8.57% |
| 2012 Q4 | 16.31 Billion INR | 0.0% |
| 2012 Q2 | 15.06 Billion INR | 0.0% |
| 2011 FY | 15.02 Billion INR | 6.68% |
| 2011 Q4 | 15.02 Billion INR | 0.0% |
| 2010 FY | 14.08 Billion INR | 16.85% |
| 2009 FY | 12.05 Billion INR | 13.14% |
| 2008 FY | 10.65 Billion INR | 16.36% |
| 2007 FY | 9.15 Billion INR | 6.68% |
| 2006 FY | 8.58 Billion INR | 23.53% |
| 2005 FY | 6.94 Billion INR | 21.59% |
| 2004 FY | 5.71 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Abbott India Limited | 51.93 Billion INR | 66.982% |
| Cipla Limited | 327.17 Billion INR | 94.759% |
| Gland Pharma Limited | 106.61 Billion INR | 83.916% |
| GlaxoSmithKline Pharmaceuticals Limited | 35.73 Billion INR | 52.017% |
| Kopran Limited | 7.43 Billion INR | -130.718% |
| Marksans Pharma Limited | 26.8 Billion INR | 36.038% |
| NGL Fine-Chem Limited | 3.55 Billion INR | -382.314% |
| Pfizer Limited | 42.28 Billion INR | 59.449% |
| SMS Pharmaceuticals Limited | 10.34 Billion INR | -65.827% |
| TTK Healthcare Limited | 12 Billion INR | -42.829% |